In fiscal 2024, which ended Jun 30, 2024, Renalytix plc used $30.1 million of cash from operations, up 11.7% from the year before.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2025
Sep 30, 2024
|
FY 2024
Jun 30, 2024
|
FY 2023
Jun 30, 2023
|
FY 2022
Jun 30, 2022
|
FY 2021
Jun 30, 2021
|
FY 2020
Jun 30, 2020
|
|---|---|---|---|---|---|---|
| Operating | ||||||
| Depreciation and amortization |
0
|
0
-28.3%
|
1
+3.9%
|
0
+73.4%
|
0
+302.9%
|
0
|
| Stock-based compensation |
1
|
2
-41.7%
|
3
-36.6%
|
5
+73.5%
|
3
+129.8%
|
1
|
| Operating cash flow |
-24
|
-30
+11.7%
|
-34
+25.8%
|
-46
-61.7%
|
-28
-198.2%
|
-10
|
| Investing | ||||||
| Capital expenditures |
—
|
—
|
0
-100.0%
|
1
-27.9%
|
1
-3.9%
|
1
|
| Investing cash flow |
0
|
-0
|
0
+100.0%
|
-1
+11.9%
|
-1
+36.0%
|
-1
|
| Financing | ||||||
| Financing cash flow |
11
|
10
-37.4%
|
16
-36.1%
|
26
-66.8%
|
77
+384.6%
|
16
|
| Change in cash | ||||||
| Effect of exchange rate |
0
|
-0
-113.1%
|
1
|
—
|
—
|
—
|
| Net change in cash |
-13
|
-20
-20.1%
|
-17
|
—
|
—
|
—
|
| Free cash flow |
—
|
—
|
-34
+26.7%
|
-46
-59.3%
|
-29
-182.5%
|
-10
|
| Per share | ||||||
| Free cash flow per share |
—
|
—
|
-0.41
+34.1%
|
-0.63
|
—
|
—
|
| Ratios | ||||||
| Free cash flow margin |
—
|
—
|
-1,001.62%
|
-1,565.02%
|
-1,956.54%
|
—
|
| Capital expenditures to revenue |
—
|
—
|
0.00%
|
18.75%
|
51.84%
|
—
|
| Stock-based compensation to revenue |
61.27%
|
74.71%
|
86.16%
|
155.59%
|
178.60%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- RNLXY (OTC), RENXF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- United Kingdom
- Headquarters
- London
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1811115
- Former names
- Renalytix AI plc (until Jun 25, 2021)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.